Review summary
Teaching objective: Evidence-based, non-stigmatizing, trauma-informed primary care for a 33-year-old singer with a severe opioid use disorder and a moderate alcohol use disorder, five weeks after release from custody, when overdose risk is highest: starting buprenorphine in primary care, naloxone and overdose education, acamprosate for alcohol because naltrexone cannot be combined with buprenorphine, PEth to follow drinking, hepatitis, HIV, and liver screening with FIB-4 fibrosis staging, hepatitis A and B vaccination, depression screening with a structured safety assessment and the 988 Suicide & Crisis Lifeline, and an integrated recovery plan that continues medication through a return to use rather than requiring linear recovery, on the ASAM, SAMHSA, VA/DoD, and AASLD guidance and the CMID depression monograph.
Historical timeline
| Date | Event | Claims |
|---|---|---|
| April 7, 1915 | Born Eleanora Fagan in Philadelphia; raised in Baltimore. | CLM-0001 |
| about 1943 | Began using heroin. | CLM-0003 |
| October 1945 | Her mother died; her drinking and drug use increased. | CLM-0002 |
| May 16, 1947 | Arrested for narcotics possession; sentenced to a year and a day. | CLM-0004 |
| March 16, 1948 | Released early from federal custody; lost her New York cabaret card. | CLM-0004, CLM-0006 |
| 1950 | Drinking increased over the following seven years. | CLM-0010 |
| 1956 | Lady Sings the Blues published. | CLM-0008 |
| July 17, 1959 | Died at Metropolitan Hospital in New York. | CLM-0009 |
Evidence claims
D = documented, R = retrospective, S = synthetic.
| Grade | Claim | Certainty | Sources |
|---|---|---|---|
| D | Billie Holiday was born Eleanora Fagan in Philadelphia on April 7, 1915, and was raised in Baltimore by her mother, Sarah Julia "Sadie" Fagan. | confirmed | Billie Holiday supports Billie Holiday Historical Marker supports Nicholson S. Holiday, Billie supports |
| D | Her mother died in October 1945; afterwards Holiday drank more heavily and her drug use increased as she grieved. The anchor for the synthetic alcohol use disorder. The cause of her mother's death is not given in the cited sources. |
confirmed | Billie Holiday supports Nicholson S. Holiday, Billie supports Billie Holiday: About the Performer supports |
| D | Holiday began using heroin in the early 1940s, and her addiction became severe in the late 1940s; she was arrested repeatedly over her heroin use in that period. The anchor for the synthetic opioid use disorder. The arrests are recorded as part of her history, without judgment. |
confirmed | Billie Holiday: About the Performer supports Billie Holiday supports Nicholson S. Holiday, Billie supports |
| D | In May 1947 Holiday was arrested for narcotics possession; she pleaded guilty, was sentenced to a year and a day, and was held at the federal facility for women at Alderson, West Virginia, until her early release on March 16, 1948. Release after a long period of enforced abstinence carries a high risk of overdose; the modern episode begins five weeks after her release. One source names the place as "Alderston, Virginia," an evident error. |
confirmed | Billie Holiday Historical Marker supports Nicholson S. Holiday, Billie supports Billie Holiday supports |
| D | Holiday sought treatment for her addiction, at one point checking herself into an institution in the hope of breaking her habit. Supports her own wish to recover, which the episode builds on. The source gives no date. |
confirmed | Billie Holiday: About the Performer supports |
| D | Her conviction cost her the New York City cabaret card she needed to perform in clubs that served alcohol. A loss of income and work tied to the conviction; part of her social history. |
confirmed | Billie Holiday Historical Marker supports Nicholson S. Holiday, Billie supports Billie Holiday: About the Performer supports |
| R | The Federal Bureau of Narcotics pursued Holiday for years, and later writers have described that pursuit as driven by racism and linked it to her performance of "Strange Fruit," a song against lynching. Retrospective interpretation by later writers; recorded to support trauma-informed care, and not used to state any person's motives as fact. |
probable | Chang R. Billie Holiday and the U.S. government's war on narcotics supports |
| D | Her autobiography, Lady Sings the Blues, written in collaboration with William Dufty, was published in 1956. After the index date; not quoted in the record. |
confirmed | Billie Holiday supports Nicholson S. Holiday, Billie supports |
| D | In 1959 Holiday was admitted to Metropolitan Hospital in New York with liver and heart problems and was diagnosed with cirrhosis. While she was in the hospital she was arrested for narcotics possession and kept under police guard. She died there on July 17, 1959, aged 44; the cause of death is given as cirrhosis of the liver with pulmonary edema, or pulmonary edema and heart failure. After the episode, recorded as a fact without detail. The episode records no liver diagnosis. One source dates her death to July 15, 1959. |
confirmed | Billie Holiday Historical Marker supports Adams J. Lady Day departs into that good night supports Billie Holiday supports Billie Holiday: About the Performer supports Nicholson S. Holiday, Billie disputes |
| D | After 1950 she slipped deeper into alcohol use over the following seven years. After the index date; supports the decision to treat her alcohol use from the start of the episode. |
confirmed | Billie Holiday: About the Performer supports |
Modern synthetic problem list
| Grade | Problem | Clinical status | Verification | Placement | Historical claims |
|---|---|---|---|---|---|
| S | Opioid use disorder (heroin), severe; in early remission in a controlled environment at intake, five weeks after release from custody; on buprenorphine; synthetic modern episode linked to her documented heroin use | active | confirmed | both_with_link | CLM-0003, CLM-0004, CLM-0005 |
| S | Alcohol use disorder, moderate; synthetic modern episode linked to her documented heavier drinking after her mother's death | active | confirmed | both_with_link | CLM-0002 |
| S | Acute periapical abscess of the lower right first molar with localized swelling, treated with an antibiotic and dental drainage; resolved | resolved | confirmed | active |
Synthetic outcome measures
| Grade | Date | Measure | Result | Coding |
|---|---|---|---|---|
| S | 2026-04-20 | Hemoglobin [Mass/volume] in Blood | 12.4 g/dL Reference 11.6-15 g/dL |
http://loinc.org · 718-7 |
| S | 2026-04-20 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 101 fL (high) Reference 80-100 fL |
http://loinc.org · 787-2 |
| S | 2026-04-20 | Platelets [#/volume] in Blood by Automated count | 236 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 2026-04-20 | Sodium [Moles/volume] in Serum or Plasma | 138 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 2026-04-20 | Potassium [Moles/volume] in Serum or Plasma | 4 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-04-20 | Creatinine [Mass/volume] in Serum or Plasma | 0.72 mg/dL Reference 0.59-1.04 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-04-20 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 113 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-04-20 | Glucose [Mass/volume] in Serum or Plasma | 88 mg/dL Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 2026-04-20 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 52 U/L (high) Reference 10-40 U/L |
http://loinc.org · 1920-8 |
| S | 2026-04-20 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 38 U/L Reference 7-56 U/L |
http://loinc.org · 1742-6 |
| S | 2026-04-20 | Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma | 84 U/L (high) Reference 5-40 U/L |
http://loinc.org · 2324-2 |
| S | 2026-04-20 | Albumin [Mass/volume] in Serum or Plasma | 4 g/dL Reference 3.5-5 g/dL |
http://loinc.org · 1751-7 |
| S | 2026-04-20 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.7 mg/dL Reference 0.1-1.2 mg/dL |
http://loinc.org · 1975-2 |
| S | 2026-04-20 | Hepatitis C virus Ab Signal/Cutoff in Serum or Plasma by Immunoassay | 0.09 Reference Below 1.00 is nonreactive |
http://loinc.org · 48159-8 |
| S | 2026-04-20 | Hepatitis B virus surface Ab [Units/volume] in Serum | 3 m[IU]/mL (low) Reference >=10 m[IU]/mL |
http://loinc.org · 16935-9 |
| S | 2026-04-20 | Phosphatidylethanol [Mass/volume] in Blood | 312 ng/mL (high) Reference Below 20 ng/mL: abstinence or light drinking; 20 to 199: significant drinking; 200 or more: heavy drinking |
http://loinc.org · 74661-0 |
| S | 2026-04-20 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 9 | http://loinc.org · 44261-6 |
| S | 2026-04-20 | Total score [AUDIT-C] | 8 | http://loinc.org · 75626-2 |
| S | 2026-04-20 | Total score [DAST-10] | 7 | http://loinc.org · 82667-7 |
| S | 2026-05-26 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 38 U/L Reference 10-40 U/L |
http://loinc.org · 1920-8 |
| S | 2026-05-26 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 30 U/L Reference 7-56 U/L |
http://loinc.org · 1742-6 |
| S | 2026-05-26 | Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma | 52 U/L (high) Reference 5-40 U/L |
http://loinc.org · 2324-2 |
| S | 2026-05-26 | Phosphatidylethanol [Mass/volume] in Blood | 96 ng/mL (high) Reference Below 20 ng/mL: abstinence or light drinking; 20 to 199: significant drinking; 200 or more: heavy drinking |
http://loinc.org · 74661-0 |
| S | 2026-05-26 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 7 | http://loinc.org · 44261-6 |
| S | 2026-07-20 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 44 U/L (high) Reference 10-40 U/L |
http://loinc.org · 1920-8 |
| S | 2026-07-20 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 33 U/L Reference 7-56 U/L |
http://loinc.org · 1742-6 |
| S | 2026-07-20 | Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma | 61 U/L (high) Reference 5-40 U/L |
http://loinc.org · 2324-2 |
| S | 2026-07-20 | Phosphatidylethanol [Mass/volume] in Blood | 164 ng/mL (high) Reference Below 20 ng/mL: abstinence or light drinking; 20 to 199: significant drinking; 200 or more: heavy drinking |
http://loinc.org · 74661-0 |
| S | 2026-07-20 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 11 | http://loinc.org · 44261-6 |
| S | 2026-08-31 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | http://loinc.org · 44261-6 |
| S | 2026-08-31 | Total score [AUDIT-C] | 3 | http://loinc.org · 75626-2 |
| S | 2026-10-19 | Hemoglobin [Mass/volume] in Blood | 12.9 g/dL Reference 11.6-15 g/dL |
http://loinc.org · 718-7 |
| S | 2026-10-19 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 95 fL Reference 80-100 fL |
http://loinc.org · 787-2 |
| S | 2026-10-19 | Platelets [#/volume] in Blood by Automated count | 248 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 2026-10-19 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 30 U/L Reference 10-40 U/L |
http://loinc.org · 1920-8 |
| S | 2026-10-19 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 26 U/L Reference 7-56 U/L |
http://loinc.org · 1742-6 |
| S | 2026-10-19 | Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma | 34 U/L Reference 5-40 U/L |
http://loinc.org · 2324-2 |
| S | 2026-10-19 | Phosphatidylethanol [Mass/volume] in Blood | 22 ng/mL (high) Reference Below 20 ng/mL: abstinence or light drinking; 20 to 199: significant drinking; 200 or more: heavy drinking |
http://loinc.org · 74661-0 |
| S | 2026-10-19 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | http://loinc.org · 44261-6 |
Synthetic vital signs
| Date | Measure | Result | LOINC | Grade |
|---|---|---|---|---|
| 2026-04-20 | Body height | 165 cm | 8302-2 | S |
| 2026-04-20 | Body weight | 68 kg | 29463-7 | S |
| 2026-04-20 | Body mass index (BMI) [Ratio] | 25 kg/m2 | 39156-5 | S |
| 2026-04-20 | Systolic blood pressure | 126 mm[Hg] | 8480-6 | S |
| 2026-04-20 | Diastolic blood pressure | 80 mm[Hg] | 8462-4 | S |
| 2026-04-20 | Heart rate | 84 /min | 8867-4 | S |
| 2026-04-20 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-04-20 | Body temperature | 36.8 Cel | 8310-5 | S |
| 2026-04-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-04-27 | Body height | 165 cm | 8302-2 | S |
| 2026-04-27 | Body weight | 68.2 kg | 29463-7 | S |
| 2026-04-27 | Body mass index (BMI) [Ratio] | 25.1 kg/m2 | 39156-5 | S |
| 2026-04-27 | Systolic blood pressure | 122 mm[Hg] | 8480-6 | S |
| 2026-04-27 | Diastolic blood pressure | 78 mm[Hg] | 8462-4 | S |
| 2026-04-27 | Heart rate | 78 /min | 8867-4 | S |
| 2026-04-27 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-04-27 | Body temperature | 36.7 Cel | 8310-5 | S |
| 2026-04-27 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-05-26 | Body height | 165 cm | 8302-2 | S |
| 2026-05-26 | Body weight | 68.6 kg | 29463-7 | S |
| 2026-05-26 | Body mass index (BMI) [Ratio] | 25.2 kg/m2 | 39156-5 | S |
| 2026-05-26 | Systolic blood pressure | 118 mm[Hg] | 8480-6 | S |
| 2026-05-26 | Diastolic blood pressure | 76 mm[Hg] | 8462-4 | S |
| 2026-05-26 | Heart rate | 74 /min | 8867-4 | S |
| 2026-05-26 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-05-26 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-05-26 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
| 2026-07-20 | Body height | 165 cm | 8302-2 | S |
| 2026-07-20 | Body weight | 67.4 kg | 29463-7 | S |
| 2026-07-20 | Body mass index (BMI) [Ratio] | 24.8 kg/m2 | 39156-5 | S |
| 2026-07-20 | Systolic blood pressure | 128 mm[Hg] | 8480-6 | S |
| 2026-07-20 | Diastolic blood pressure | 82 mm[Hg] | 8462-4 | S |
| 2026-07-20 | Heart rate | 86 /min | 8867-4 | S |
| 2026-07-20 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-07-20 | Body temperature | 36.8 Cel | 8310-5 | S |
| 2026-07-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-10-19 | Body height | 165 cm | 8302-2 | S |
| 2026-10-19 | Body weight | 69 kg | 29463-7 | S |
| 2026-10-19 | Body mass index (BMI) [Ratio] | 25.3 kg/m2 | 39156-5 | S |
| 2026-10-19 | Systolic blood pressure | 116 mm[Hg] | 8480-6 | S |
| 2026-10-19 | Diastolic blood pressure | 74 mm[Hg] | 8462-4 | S |
| 2026-10-19 | Heart rate | 72 /min | 8867-4 | S |
| 2026-10-19 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-10-19 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-10-19 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
| 2026-08-31 | Body height | 165 cm | 8302-2 | S |
| 2026-08-31 | Body weight | 68.8 kg | 29463-7 | S |
| 2026-08-31 | Body mass index (BMI) [Ratio] | 25.3 kg/m2 | 39156-5 | S |
| 2026-08-31 | Systolic blood pressure | 118 mm[Hg] | 8480-6 | S |
| 2026-08-31 | Diastolic blood pressure | 76 mm[Hg] | 8462-4 | S |
| 2026-08-31 | Heart rate | 74 /min | 8867-4 | S |
| 2026-08-31 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-08-31 | Body temperature | 36.7 Cel | 8310-5 | S |
| 2026-08-31 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
| 2026-09-21 | Body height | 165 cm | 8302-2 | S |
| 2026-09-21 | Body weight | 68.4 kg | 29463-7 | S |
| 2026-09-21 | Body mass index (BMI) [Ratio] | 25.1 kg/m2 | 39156-5 | S |
| 2026-09-21 | Systolic blood pressure | 130 mm[Hg] | 8480-6 | S |
| 2026-09-21 | Diastolic blood pressure | 82 mm[Hg] | 8462-4 | S |
| 2026-09-21 | Heart rate | 92 /min | 8867-4 | S |
| 2026-09-21 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-09-21 | Body temperature | 37.6 Cel | 8310-5 | S |
| 2026-09-21 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
Social, functional, and mental status
Social history
- S Professional singer; returned to concert work and touring after her release; can no longer work in clubs in her home city because of a licensing rule tied to her conviction
- S Returned home five weeks ago after about ten months in federal custody on a narcotics possession charge; no medication for opioid use disorder was offered there, and she has used no opioids since release
- S Alcohol: four or five drinks on most performance nights since release (AUDIT-C 8); drinks to calm her nerves before and after shows
- S Tobacco: about five cigarettes a day; not ready to stop now and knows help is available
- S Supports: musicians she has worked with for years, a close friend who has agreed to carry naloxone, and a peer recovery coach; her music is her strongest source of purpose
- S Has repeatedly been singled out by law enforcement and feels watched; wary of clinics and of anything written about her. Confidentiality under the federal substance use disorder privacy rule explained, and she decides what is shared
Functional status
- S Independent in all activities; performing several nights a week; sleep broken since release
Mental status
- S Alert, guarded at first and then candid; speech normal; no signs of intoxication or withdrawal
- S Mood low and tired, with grief for her mother that still returns; PHQ-9 score 9 with item 9 scored 0; no thoughts of suicide or self-harm
Structured safety assessment
This assessment is synthetic and does not convert historical behavior into a present-day fact.
Allergies and medications
Allergies
- S No known allergy
Medications
- S Buprenorphine 8 mg and naloxone 2 mg sublingual film: half a film (4 mg) on day 1, then one film (8 mg) under the tongue daily
- S Buprenorphine 8 mg and naloxone 2 mg sublingual film, two films (16 mg) under the tongue once daily
- S Naloxone 4 mg nasal spray, one spray in one nostril for a suspected opioid overdose; may repeat every 2 to 3 minutes in alternating nostrils; call 911
- S Acamprosate 333 mg delayed-release oral tablet, two tablets (666 mg) by mouth three times daily
- S Thiamine 100 mg oral tablet, one tablet by mouth daily
- S Amoxicillin 500 mg oral capsule, one capsule by mouth three times daily for seven days
- S Ibuprofen 400 mg oral tablet, one tablet by mouth every 6 to 8 hours with food as needed for tooth pain, for up to five days
- S Acetaminophen 500 mg oral tablet, two tablets by mouth every 8 hours as needed for tooth pain, no more than 3,000 mg a day, for up to five days
Procedures and immunizations
Procedures
- S Advance care planning conversation, about 16 minutes
Immunizations
- S 2026-04-20: Tdap vaccine
- S 2026-04-20: Hepatitis B vaccine (HepB-CpG), dose 1 of 2
- S 2026-04-20: Hepatitis A vaccine, adult, dose 1 of 2
- S 2026-04-20: Pneumococcal conjugate vaccine PCV20
- S 2026-05-26: Hepatitis B vaccine (HepB-CpG), dose 2 of 2
- S 2026-10-19: Hepatitis A vaccine, adult, dose 2 of 2
- S 2026-10-19: Influenza vaccine, 2026-2027 season
Past medical history
True biography with historical dates; not part of the synthetic care timeline.
- D about 1943: Heroin use from the early 1940s, becoming a severe addiction in the late 1940s; sought treatment for it at least once (CLM-0003, CLM-0005)
- D October 1945: Heavier drinking and increased drug use after her mother's death (CLM-0002)
- D March 16, 1948: Federal custody after a narcotics possession conviction, about ten months with enforced abstinence; released early (CLM-0004)
Family history
- D mother: Died in 1945; cause not recorded in the cited source
Care-plan goals
| Goal | Target date | Status | Outcome |
|---|---|---|---|
| Stay on buprenorphine without interruption through six months, including through any return to use | 2026-10-19 | completed | Taking buprenorphine 16 mg daily at six months; a three-day gap during a tour was followed by a brief return to use and an immediate restart, with no overdose |
| Naloxone at home and in her bag, and a friend trained to use it, by the one-week visit | 2026-04-27 | completed | Two naloxone two-packs dispensed; her friend trained |
| Reduce drinking to PEth below 20 ng/mL, or to the level she chooses, by six months | 2026-10-19 | completed | PEth 22 ng/mL from 312; occasional light drinking, which she chose |
| Hepatitis A and B vaccine series completed by six months | 2026-10-19 | completed | Hepatitis B doses at intake and five weeks; hepatitis A doses at intake and six months |
| PHQ-9 score below 5 by six months | 2026-10-19 | completed | PHQ-9 4 |
Interventions
| Intervention | Status | Guideline |
|---|---|---|
| Buprenorphine with naloxone started in primary care at a low first dose, then 16 mg daily, continued through any return to use; naloxone, overdose education, never using alone, and fentanyl test strips | completed | GL-ASAM-OUD-2020, GL-SAMHSA-MOUD, GL-SUD-2021 |
| Addiction medicine consultation to confirm the medication plan, choose a medicine for alcohol use disorder that can be used with buprenorphine, and set the monitoring plan | completed | GL-ASAM-OUD-2020, GL-SUD-2021 |
| Alcohol care: acamprosate, thiamine, brief counseling and goals she chooses, and PEth at each check to follow drinking without relying on memory | completed | GL-SUD-2021, GL-SAMHSA-MOUD |
| Liver and infection screening: liver tests and FIB-4 at intake and six months, hepatitis C antibody, hepatitis B triple panel, and HIV test, with hepatitis A and B vaccines for a person who is not immune | completed | GL-AASLD-ALD-2019, GL-AASLD-NIT-2025, GL-CDC-HBV-2023, GL-USPSTF-HCV-2020, GL-USPSTF-HIV-2019 |
| Depression screening with the PHQ-9 at each recovery visit, a structured safety assessment with a written safety plan and the 988 Suicide & Crisis Lifeline, and safety review at every visit | completed | GL-CMID-2026, GL-USPSTF-DEP-2023, GL-SUICIDE-2024 |
| Integrated, trauma-informed recovery plan: weekly counseling, a peer recovery coach, confidentiality she controls, and a written plan for touring, without requiring recovery to be perfect or linear | completed | GL-SUD-2021, GL-SAMHSA-MOUD |
Planned encounters
- 2026-04-20 — Establishing primary care five weeks after release from custody: medication for opioid use disorder, overdose prevention, alcohol care, liver and infection screening, and depression and safety screening (ENC-001)
- 2026-04-27 — One-week buprenorphine check and addiction medicine consultation (ENC-002)
- 2026-05-26 — Five-week recovery review and second hepatitis B vaccine (ENC-003)
- 2026-07-20 — Three-month review after a return to opioid use: adjusting the recovery plan (ENC-004)
- 2026-08-31 — Periodic adult preventive visit (ENC-006)
- 2026-09-21 — Same-day sick visit for a dental abscess (ENC-007, unscheduled)
- 2026-10-19 — Six-month recovery, alcohol, liver, and mood review (ENC-005)
Supporting documents
- History and physical
- Progress note 01
- Progress note 02 — Focused Visit (Follow-up)
- Progress note 03 — Focused Visit (Follow-up)
- Progress note 04 — Focused Visit (Follow-up)
- Progress note 05 — Preventive Visit
- Progress note 06 — Sick Visit
- Progress note 07 — Focused Visit (Care-plan review)
- Addiction Medicine referral
- Addiction Medicine consultation
- Patient care plan
- Teaching note
- Provenance CSV
C-CDA note documents
Each link opens a readable copy; the XML beside it is the exchange file.
- History and physical (XML)
- Progress note 01 (XML)
- Progress note 02 — Focused Visit (Follow-up) (XML)
- Progress note 03 — Focused Visit (Follow-up) (XML)
- Progress note 04 — Focused Visit (Follow-up) (XML)
- Progress note 05 — Preventive Visit (XML)
- Progress note 06 — Sick Visit (XML)
- Progress note 07 — Focused Visit (Care-plan review) (XML)
- Addiction Medicine referral (XML)
- Addiction Medicine consultation (XML)
Sources
| ID | Source | Publisher | Type |
|---|---|---|---|
| SRC-0001 | Billie Holiday: About the Performer | PBS American Masters (WNET) | other |
| SRC-0002 | Billie Holiday | Biography.com (A&E Television Networks) | other |
| SRC-0003 | Billie Holiday Historical Marker | Clio (African American History of Philadelphia Heritage Trail, Saint Vincent College) | scholarly |
| SRC-0004 | Nicholson S. Holiday, Billie | Jazz.com encyclopedia | other |
| SRC-0005 | Chang R. Billie Holiday and the U.S. government's war on narcotics | Biography.com (A&E Television Networks) | other |
| SRC-0006 | Adams J. Lady Day departs into that good night | The Globe and Mail | other |
| SRC-0007 | HISTMED Master Roster v3 | The Human Record project | other |
Review status
| Review | Status | Notes |
|---|---|---|
| schema validation | not_started | Run scripts/build.ps1 -Conformance. |
| clinical review | not_started | Awaiting clinician review; check the low first buprenorphine dose after enforced abstinence, acamprosate rather than naltrexone, and the FIB-4 interpretation. |
| provenance review | not_started | PBS American Masters, Biography.com, Clio (Saint Vincent College), the Jazz.com encyclopedia, and The Globe and Mail logged. The account of racially motivated targeting is graded R. Her autobiography was not fetched and is not quoted. |
| safe messaging review | not_started | Substance-use claims are marked sensitive; person-first language throughout; arrests and custody recorded without judgment and never as her fault; the return to use is managed without blame or discharge; the safety assessment gives the 988 Suicide & Crisis Lifeline; death recorded without detail. |
Comments and corrections
Sign in with GitHub to comment on this record. To report a specific error, ideally with a source, use the feedback form; each report becomes a tracked issue.
Comments appear on the online version of this page.